Clinical Trials

327 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06144944 2026-01-30

Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer

160 enrolled

Breast Neoplasms

NCT03801876 2026-01-14

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

300 enrolled

Clinical Stage I Esophageal Adenocarcinoma AJCC v8

NCT04095364 2026-01-14

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

450 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05624996 2026-01-14

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

474 enrolled

Lung Neoplasms

NCT06908993 2025-12-17

COMET

133 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06914011 2025-12-03

MRD2START

172 enrolled

Esophageal Neoplasms

NCT04193059 2025-11-26

PANSY

1,560 enrolled

Breast Neoplasms

NCT03977194 2025-11-18

ELDERLY

510 enrolled

Non Small Cell Lung Cancer Metastatic

NCT03264547 2025-09-29

A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab

446 enrolled

Breast Neoplasms

NCT04158362 2025-09-22

AMBRE

180 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT04335669 2025-09-12

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

325 enrolled

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02514681 2025-09-10

PRECIOUS

226 enrolled

Breast Neoplasms

NCT05009082 2025-09-10

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

970 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06992882 2025-07-18

A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)

2,306 enrolled

HER2-positive Breast Cancer

NCT05357846 2025-06-12

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

422 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06980545 2025-05-20

Total Neoadjuvant 6 Cycles of Chemotherapy Versus 3 Cycles in Partial Responder Patients Diagnosed With Epithelial Ovarian Cancer

50 enrolled

Stage III and IV Ovarian Cancer

NCT03603184 2025-05-09

AtTEnd

549 enrolled

Neoplasms, Endometrial Neoplasms

NCT04585490 2025-05-06

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

48 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03085004 2025-04-17

CHARM

75 enrolled

Pancreatic Cyst

NCT04564157 2025-04-10

NADIM-ADJUVANT

210 enrolled

Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT02305654 2025-04-02

InPACT

200 enrolled

Genitourinary

Penile Neoplasms

NCT04296175 2025-03-26

CITRINE

808 enrolled

Triple Negative Breast Neoplasms

NCT06870565 2025-03-17

Comparative Study of Adjuvant Therapy for Postoperative Cervical Gastric-type Adenocarcinoma

238 enrolled

Uterine Cervical Neoplasms

NCT02214381 2025-02-27

A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response

80 enrolled

Breast Neoplasms

NCT04732598 2025-02-05

AMBITION

280 enrolled

Breast Neoplasms

NCT05601700 2025-01-27

LEPRE

132 enrolled

Carcinoma, Ovarian Epithelial

NCT02375204 2025-01-13

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors

420 enrolled

Nonseminomatous germ cell tumor, Choriocarcinoma, Neoplasms, Germ Cell and Embryonal, Teratoma, Germinoma, Seminoma, Endodermal Sinus Tumor

NCT01566240 2024-12-05

INTERLACE

500 enrolled

Uterine Cervical Neoplasms

NCT04723875 2024-11-01

Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline

306 enrolled

Uterine Cervical Neoplasms

NCT03598270 2024-08-30

ANITA

417 enrolled

Ovarian Neoplasms

NCT02037529 2024-08-20

Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer

Phase 3 Suspended

201 enrolled 19 charts

Breast Neoplasms

NCT02501954 2024-07-23

Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol

48 enrolled

Endometrial Clear Cell Adenocarcinoma

NCT04158440 2024-07-09

Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC

501 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02344472 2024-06-04

Detect V / CHEVENDO (Chemo vs. Endo)

271 enrolled

Breast Neoplasms

NCT04540692 2024-06-04

NEOSAMBA

444 enrolled

Breast Neoplasms

NCT02488967 2024-06-03

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

782 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00433420 2024-05-08

Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer

2,000 enrolled

Breast Neoplasms

NCT02509286 2024-05-08

ESOPEC

438 enrolled

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms

NCT01820858 2024-04-02

EC-01

300 enrolled

Endometrial Neoplasms

NCT01996267 2024-03-29

TRAIN-2

437 enrolled

Breast Neoplasms

NCT01822314 2024-03-07

ETNA

632 enrolled

Breast Neoplasms, Neoplasms

NCT03595592 2024-03-06

APTneo

650 enrolled

Invasive Breast Cancer

NCT00411138 2023-10-11

PORTEC-3

Phase 3 Unknown

670 enrolled

Endometrial Neoplasms

NCT03534713 2023-09-21

ONCOCOL01

310 enrolled

Uterine Cervical Neoplasms

NCT01303679 2023-09-06

1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer

Phase 3 Terminated

117 enrolled

First Line Metastatic Breast Cancer

NCT04201561 2023-06-26

SELENIUM

Phase 3 Unknown

68 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peripheral Nervous System Diseases

NCT05841381 2023-05-03

Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer

876 enrolled

Breast Neoplasms

NCT02429687 2023-04-25

MOGCT-01

129 enrolled